Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
NCT00004906
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating women who have metastatic breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
05/29/2013
Locations: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois +3 locations
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
NCT00004188
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation with treated peripheral stem cells following combination chemotherapy to see how well it works compared to peripheral stem cell trans... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
05/16/2013
Locations: Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama +95 locations
Conditions: Neuroblastoma
Register for Updates
Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer
NCT00601796
Completed
The purpose of this study is to find out what effects (good and/or bad) a tumor vaccine used in combination with two drugs (ATRA and cytoxan) have on the patient and their cancer. We also want to find out if the vaccine and the drugs can boost the patient's immune system and how their immune system reacts, both before and after the vaccine treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2013
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Lung Cancer
Register for Updates
Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
NCT01219907
Withdrawn
RATIONALE : Laboratory-treated T cells may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vaccines made from HER2 peptides may help the body build an effective immune response to kill tumor cells that express HER2. Giving laboratory-treated T cells and cyclophosphamide after vaccine therapy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2013
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington
Conditions: HER2-positive Breast Cancer, Male Breast Cancer, Stage IV Breast Cancer
Register for Updates
Denileukine Diftitox for Relapsed ALCL
NCT00801918
Withdrawn
The purpose of this study is to determine is Denileukin diftitox will be safe, well tolerated and induce a significant overall response alone and in combination with chemotherapy: ifosfamide, carboplatin and etoposide (ICE) and will be safe and well tolerated in a population of children, adolescents and young adults with relapsed or refractory anaplastic large cell lymphoma (ALCL).
Gender:
ALL
Ages:
Between 2 years and 24 years
Trial Updated:
05/14/2013
Locations: Columbia University Medical Center, New York, New York
Conditions: Anaplastic Large-Cell Lymphoma
Register for Updates
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
NCT00381173
Completed
The purpose of this study is to evaluate the feasibility, safety, and tolerability of administering ZYC300 with Cyclophosphamide (Cytoxan).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2013
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, Ovarian Cancer, Prostate Cancer, Colon Cancer, Renal Cancer
Register for Updates
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
NCT00060255
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation or autologous bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well eight different high-dose chemotherapy regimens with or without... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
05/07/2013
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Register for Updates
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
NCT00066417
Terminated
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is stu... Read More
Gender:
ALL
Ages:
Between 10 years and 50 years
Trial Updated:
04/30/2013
Locations: NIH - Warren Grant Magnuson Clinical Center, Bethesda, Maryland
Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
Register for Updates
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
NCT00715208
Completed
This is a phase 2, two-arm, non-randomized, open-label, multicenter study evaluating the safety and efficacy of 2 VELCADE-containing regimens. Patients will be treated with either a combination of VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone (VELCADE-R-CAP) or a combination of VELCADE, rituximab, cyclophosphamide, and prednisone (VELCADE-R-CP) based on investigator preference. Following completion of the treatment period, patients will receive maintenance therapy with rituxi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2013
Locations: Northwest Alabama Center, PC, Muscle Shoals, Alabama +42 locations
Conditions: Relapsed Follicular Lymphoma
Register for Updates
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
NCT00003425
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of high-dose melphalan plus peripheral stem cell transplantation... Read More
Gender:
ALL
Ages:
Between 14 years and 70 years
Trial Updated:
04/25/2013
Locations: Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky +3 locations
Conditions: Breast Cancer, Leukemia, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
NCT00126191
Terminated
The purpose of this study is to learn more about how well a chemotherapy regime including rituximab works in treating patients with Burkitt or atypical Burkitt lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2013
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Burkitt Lymphoma, Non-Hodgkins Lymphoma, Atypical Burkitt Lymphoma
Register for Updates
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00003944
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating patients who have stage III or stage IV ovarian, fallopian tube, or primary peritoneal can... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/16/2013
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates